Blockade of SOX4 mediated DNA repair by SPARC enhances radioresponse in medulloblastoma

Cancer Letters

Volumn 323, Issue 2, 2012, Pages 188-198

  Chetty, Chandramu ^a   Dontula, Ranadheer ^b   Gujrati, Meena ^a   Dinh, Dzung H ^a   Lakka, Sajani S ^b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Medulloblastoma; Radiosensitization; SOX4; SPARC

Indexed keywords

OSTEONECTIN; PROTEIN P53; TRANSCRIPTION FACTOR SOX4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DNA REPAIR; FLUORESCENCE ACTIVATED CELL SORTING; GENE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MEDULLOBLASTOMA; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; XRCC1 GENE;

BASE SEQUENCE; CELL DIVISION; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; DNA PRIMERS; DNA REPAIR; G2 PHASE; HISTONES; HUMANS; IN SITU NICK-END LABELING; MEDULLOBLASTOMA; OSTEONECTIN; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOXC TRANSCRIPTION FACTORS;

EID: 84863105129     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.04.014     Document Type: Article

References (42)

1. Packer R.J., Allen J.C., Goldwein J.L., Newall J., Zimmerman R.A., Priest J., Tomita T., Mandelbaum D.E., Cohen B.H., Finlay J.L. Hyperfractionated radiotherapy for children with brainstem gliomas: a pilot study using 7200 cGy. Ann. Neurol. 1990, 27:167-173.
2. Deutsch M., Thomas P.R., Krischer J., Boyett J.M., Albright L., Aronin P., Langston J., Allen J.C., Packer R.J., Linggood R., Mulhern R., Stanley P., Stehbens J.A., Duffner P., Kun L., Rorke L., Cherlow J., Freidman H., Finlay J.L., Vietti T. Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3600 cGy/20) with reduced neuraxis irradiation (2340 cGy/13) in patients with low-stage medulloblastoma. A combined children's cancer group-pediatric oncology group study. Pediatr. Neurosurg. 1996, 24:167-176.
3. Li L., Story M., Legerski R.J. Cellular responses to ionizing radiation damage. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49:1157-1162.
4. McBride W.H., Dougherty G.J. Radiotherapy for genes that cause cancer. Nat. Med. 1995, 1:1215-1217.
5. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin. Radiat. Oncol. 2004, 14:198-206.
6. Bornstein P., Sage E.H. Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 2002, 14:608-616.
7. Ledda M.F., Adris S., Bravo A.I., Kairiyama C., Bover L., Chernajovsky Y., Mordoh J., Podhajcer O.L. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med. 1997, 3:171-176.
8. Rempel S.A., Ge S., Gutierrez J.A. SPARC: a potential diagnostic marker of invasive meningiomas. Clin. Cancer Res. 1999, 5:237-241.
9. Yiu G.K., Chan W.Y., Ng S.W., Chan P.S., Cheung K.K., Berkowitz R.S., Mok S.C. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am. J. Pathol. 2001, 159:609-622.
10. Brekken R.A., Puolakkainen P., Graves D.C., Workman G., Lubkin S.R., Sage E.H. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J. Clin. Invest. 2003, 111:487-495.
11. Puolakkainen P.A., Brekken R.A., Muneer S., Sage E.H. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol. Cancer Res. 2004, 2:215-224.
12. Tai I.T., Dai M., Owen D.A., Chen L.B. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J. Clin. Invest. 2005, 115:1492-1502.
13. Bhoopathi P., Chetty C., Gujrati M., Dinh D.H., Rao J.S., Lakka S.S. Cathepsin B facilitates autophagy mediated apoptosis in SPARC overexpressed primitive neuroectodermal tumor cells. Cell Death Differ. 2010, 17:1529-1539.
14. Phelan C.M., Liu L., Ruttledge M.H., Müntzning K., Ridderheim P.A., Collins V.P. Chromosome 17 abnormalities and lack of TP53 mutations in paediatric central nervous system tumours. Hum. Genet. 1995, 96:684-690.
15. Saylors R.L., Sidransky D., Friedman H.S., Bigner S.H., Bigner D.D., Vogelstein B., Brodeur G.M. Infrequent p53 gene mutations in medulloblastomas. Cancer Res. 1991, 51:4721-4723.
16. Bigner S.H., Friedman H.S., Vogelstein B., Oakes W.J., Bigner D.D. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res. 1990, 50:2347-2350.
17. Bhoopathi P., Chetty C., Gujrati M., Dinh D.H., Rao J.S., Lakka S.S. The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine. Br. J. Cancer 2010, 102:530-540.
18. Chetty C., Lakka S.S., Bhoopathi P., Gondi C.S., Veeravalli K.K., Fassett D., Klopfenstein J.D., Dinh D.H., Gujrati M., Rao J.S. Urokinase plasminogen activator receptor and/or matrix metalloproteinase-9 inhibition induces apoptosis signaling through lipid rafts in glioblastoma xenograft cells. Mol. Cancer Ther. 2010, 9:2605-2617.
19. Schmidt K.F., Ziu M., Schmidt N.O., Vaghasia P., Cargioli T.G., Doshi S., Albert M.S., Black P.M., Carroll R.S., Sun Y. Volume reconstruction techniques improve the correlation between histological and in vivo tumor volume measurements in mouse models of human gliomas. J. Neurooncol. 2004, 68:207-215.
20. Bhoopathi P., Chetty C., Dontula R., Gujrati M., Dinh D.H., Rao J.S., Lakka S.S. SPARC stimulates neuronal differentiation of medulloblastoma cells via the Notch1/STAT3 pathway. Cancer Res. 2011, 71:4908-4919.
21. Lu C., Zhu F., Cho Y.Y., Tang F., Zykova T., Ma W.Y., Bode A.M., Dong Z. Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. Mol. Cell 2006, 23:121-132.
22. Redon C., Pilch D., Rogakou E., Sedelnikova O., Newrock K., Bonner W. Histone H2A variants H2AX and H2AZ. Curr. Opin. Genet. Dev. 2002, 12:162-169.
23. Nyberg K.A., Michelson R.J., Putnam C.W., Weinert T.A. Toward maintaining the genome: DNA damage and replication checkpoints. Annu. Rev. Genet. 2002, 36:617-656.
24. Zhou B.B., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 2000, 408:433-439.
25. Harms K., Nozell S., Chen X. The common and distinct target genes of the p53 family transcription factors. Cell. Mol. Life Sci. 2004, 61:822-842.
26. Pan X., Zhao J., Zhang W.N., Li H.Y., Mu R., Zhou T., Zhang H.Y., Gong W.L., Yu M., Man J.H., Zhang P.J., Li A.L., Zhang X.M. Induction of SOX4 by DNA damage is critical for p53 stabilization and function. Proc. Natl. Acad. Sci. USA 2009, 106:3788-3793.
27. Collis S.J., Swartz M.J., Nelson W.G., DeWeese T.L. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res. 2003, 63:1550-1554.
28. Sak A., Stueben G., Groneberg M., Bocker W., Stuschke M. Targeting of Rad51-dependent homologous recombination: implications for the radiation sensitivity of human lung cancer cell lines. Br. J. Cancer 2005, 92:1089-1097.
29. Schaue D., McBride W.H. Counteracting tumor radioresistance by targeting DNA repair. Mol. Cancer Ther. 2005, 4:1548-1550.
30. Zhang L., Yoo S., Dritschilo A., Belyaev I., Soldatenkov V. Targeting Ku protein for sensitizing of breast cancer cells to DNA-damage. Int. J. Mol. Med. 2004, 14:153-159.
31. Kroemer G., Galluzzi L., Vandenabeele P., Abrams J., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., El-Deiry W.S., Golstein P., Green D.R., Hengartner M., Knight R.A., Kumar S., Lipton S.A., Malorni W., Nunez G., Peter M.E., Tschopp J., Yuan J., Piacentini M., Zhivotovsky B., Melino G. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ. 2009, 16:3-11.
32. Ricci M.S., Zong W.X. Chemotherapeutic approaches for targeting cell death pathways. Oncologist 2006, 11:342-357.
33. Castedo M., Perfettini J.L., Roumier T., Andreau K., Medema R., Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004, 23:2825-2837.
34. Chen Z., Xiao Z., Chen J., Ng S.C., Sowin T., Sham H., Rosenberg S., Fesik S., Zhang H. Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol. Cancer Ther. 2003, 2:543-548.
35. Roninson I.B., Broude E.V., Chang B.D. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist. Updat. 2001, 4:303-313.
36. Hoser M., Baader S.L., Bosl M.R., Ihmer A., Wegner M., Sock E. Prolonged glial expression of Sox4 in the CNS leads to architectural cerebellar defects and ataxia. J. Neurosci. 2007, 27:5495-5505.
37. Nissen-Meyer L.S., Jemtland R., Gautvik V.T., Pedersen M.E., Paro R., Fortunati D., Pierroz D.D., Stadelmann V.A., Reppe S., Reinholt F.P., Del Fattore A., Rucci N., Teti A., Ferrari S., Gautvik K.M. Osteopenia, decreased bone formation and impaired osteoblast development in Sox4 heterozygous mice. J. Cell Sci. 2007, 120:2785-2795.
38. Wilson M.E., Yang K.Y., Kalousova A., Lau J., Kosaka Y., Lynn F.C., Wang J., Mrejen C., Episkopou V., Clevers H.C., German M.S. The HMG box transcription factor Sox4 contributes to the development of the endocrine pancreas. Diabetes 2005, 54:3402-3409.
39. de Bont J.M., Kros J.M., Passier M.M., Reddingius R.E., Sillevis Smitt P.A., Luider T.M., den Boer M.L., Pieters R. Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis. Neuro Oncol. 2008, 10:648-660.
40. Lee C.J., Appleby V.J., Orme A.T., Chan W.I., Scotting P.J. Differential expression of SOX4 and SOX11 in medulloblastoma. J. Neurooncol. 2002, 57:201-214.
41. Liu P., Ramachandran S., Ali S.M., Scharer C.D., Laycock N., Dalton W.B., Williams H., Karanam S., Datta M.W., Jaye D.L., Moreno C.S. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res. 2006, 66:4011-4019.
42. Hur E.H., Hur W., Choi J.Y., Kim I.K., Kim H.Y., Yoon S.K., Rhim H. Functional identification of the pro-apoptotic effector domain in human Sox4. Biochem. Biophys. Res. Commun. 2004, 325:59-67.